Genomics Collaborative Announces the Appointment of Director of Population Genetics.Business/Health Editors CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 2, 2001 Genomics Collaborative, Inc. (GCI GCI Ground Circuit Interrupter GCI Getty Conservation Institute GCI Global Commerce Initiative GCI Green Cross International (non-profit international environmental organization) GCI Growth Competitiveness Index GCI Great Cities Institute ) announced today the appointment of Spencer Wells, Ph.D. to the position of Director of Population Genetics Population genetics The study of both experimental and theoretical consequences of mendelian heredity on the population level, in contradistinction to classical genetics which deals with the offspring of specified parents on the familial level. . Population genetics allows us to make the crucial connection between large-scale patterns we see in a set of patients with a disease and the individual likelihood of having a particular genetic variant. "Dr. Wells brings us another outstanding investigator to help us leverage our Global Repository(TM) in a rapid fashion," said Michael J. Pellini, M.D., Chief Executive Officer of Genomics Collaborative. "Our drug development process begins with association studies that are conducted based on the highest scientific standards. Our unique discovery resources are helping us attract not only significant industry and academic partners, but some of brightest scientists in the field today." Dr. Kristin Ardlie, Vice President of Genetics, adds. "Dr. Wells joins us with an impressive background in human population genetic and demographic research. Only within the context of such a framework can the full spectrum of genetic variation and patterns of linkage disequilibria present in current human populations be interpreted, and this is clearly important for the successful implementation of disease gene mapping gene mapping n. The determination of the sequence of genes and their relative distances from one another on a specific chromosome. approaches." Dr. Wells joined GCI after serving as Head of the Population Genetics group at the Wellcome Trust Centre for Human Genetics, Oxford University. Dr. Wells pursued postdoctoral studies with Sir Walter Bodmer at Oxford University and Dr. Luca Cavalli-Sforza at Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. . He received his Ph.D. from Harvard University and his B.S. from The University of Texas at Austin “University of Texas” redirects here. For other system schools, see University of Texas System. The University of Texas at Austin (often referred to as The University of Texas, UT Austin, UT, or Texas . Dr. Wells has held fellowships and grants from the Howard Hughes Medical Institute Howard Hughes Medical Institute, (HHMI), nonprofit medical research organization founded in 1953 by Howard Hughes and largly funded from proceeds of the 1984–85 sale of Hughes Aircraft. Headquartered in Chevy Chase, Md. , the National Science Foundation, the Alfred P. Sloan Foundation The Alfred P. Sloan Foundation is a philanthropic non-profit organization in the United States. It was established in 1934 by Alfred P. Sloan, Jr., then-President and Chief Executive Officer of General Motors. and NATO NATO: see North Atlantic Treaty Organization. NATO in full North Atlantic Treaty Organization International military alliance created to defend western Europe against a possible Soviet invasion. . Genomics Collaborative, Inc. ("GCI" or the "Company") is a genomics company focused on discovering previously unknown relationships between human genetic variation and the nature of important diseases. The Company's scientific strategy is to utilize its LARGE SCALE GLOBAL GENOMICS Platform in exploiting the power of appropriately designed genetic associations studies. Such studies are designed to detect subtle associations between genetic variation and disease incidence, severity or treatment, and are dependent upon the availability of large numbers of well-characterized patients and the tools with which to analyze their genetic information. GCI intends to conduct these studies and apply any resulting discoveries to the development of high value pharmaceutical products pursuant to collaborations with pharmaceutical, biotechnology and genomics companies, and on its own. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion